Trial Information
Cytogenetic and Molecular Genetic Studies in Bone Sarcomas
Inclusion Criteria:
- Patients must be undergoing diagnostic biopsy or resection of their primary or
metastatic bone sarcoma for therapeutic purposes.
- The specimen must be large enough to allow routine pathological analysis, with the
specimen for research excised from residual tissue that would otherwise be discarded.
Exclusion Criteria:
- N/A
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
To establish a serial ascertainement of specimens from patients with bone sarcomas to be used in ongoing cytogenetic and molecular genetic analyses.
Outcome Time Frame:
conclusion of study
Safety Issue:
No
Principal Investigator
Marc Ladanyi, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Memorial Sloan-Kettering Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
93-141
NCT ID:
NCT00579930
Start Date:
December 1993
Completion Date:
December 2010
Related Keywords:
- Lung Cancer
- Bone
- Soft Tissue
- Lung Neoplasms
- Osteosarcoma
- Sarcoma
Name | Location |
Memorial Sloan-Kettering Cancer Center |
New York, New York 10021 |